Pharmaceutical care for a patient with atrial flutter，atrial fibrillation，placenta praevia hemorrhage and throm-bocytopenia-threatened abortion after operation of congenital heart disease
- VernacularTitle:1例先天性心脏病术后房扑伴房颤合并前置胎盘出血及血小板减少先兆流产患者的药学监护
- Author:
Qing WANG
1
;
Shuyan QUAN
1
Author Information
1. Dept. of Pharmacy，the Second Affiliated Hospital of Army Medical University，Chongqing 400037，China
- Publication Type:Journal Article
- Keywords:
postoperative congenital heart disease;
atrial flutter;
atrial fibrillation;
thrombocytopenia;
placenta praevia
- From:
China Pharmacy
2024;35(8):1006-1010
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To provide a reference for the safe administration of patients with atrial flutter， atrial fibrillation， placenta praevia hemorrhage and thrombocytopenia-threatened abortion after the operation of congenital heart disease. METHODS Clinical pharmacists participated in the diagnosis and treatment of a patient with atrial flutter， atrial fibrillation， placenta praevia hemorrhage and thrombocytopenia-threatened abortion after the operation of congenital heart disease. Given the thrombocytopenia caused by enoxaparin sodium， pharmacists suggested to stop enoxaparin sodium and change it to fondaparinux sodium after a blood routine review. For the patient with fast heart rate and low blood pressure， pharmacists recommended to choose metoprolol and adjust the dosage according to the heart rate， and change furosemide to hydrochlorothiazide. Pharmacists recommended to continue using metoprolol regarding doctors’ plan to replace metoprolol with sotalol before cesarean section. For possible drug interactions in the patient， pharmacists recommended to closely monitor blood potassium and other indicators， and provided drug education. RESULTS The doctors adopted the advice of clinical pharmacists. The patient’s bleeding was controlled， the indicators were kept stable during hospitalization， the gestational week was extended smoothly， and the cesarean section was successfully performed. CONCLUSIONS By participating in the treatment of the patient with atrial flutter， atrial fibrillation， placenta praevia hemorrhage and thrombocytopenia-threatened abortion after the operation of congenital heart disease， clinical pharmacists formulate individualized medication plans for the patient based on adverse drug reactions， drug interactions and medication education， ensuring the safety and effectiveness of medication.
